Journal of veterinary internal medicine · 2025
Effect of Phenylbutazone Administration on Insulin Sensitivity in Horses With Insulin Dysregulation.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kemp Kate L, Yuen Nicholas K Y, Skinner Jazmine E, Bertin François-René
Аннотация
BACKGROUND: Phenylbutazone is prescribed to manage pain caused by hyperinsulinemia-associated laminitis. Phenylbutazone reduces glucose and insulin concentrations in horses with insulin dysregulation (ID) but the underlying mechanism of action is unknown.
HYPOTHESIS/OBJECTIVES: Investigate the effect of phenylbutazone on tissue insulin sensitivity in horses. It is hypothesized that the reduced glucose and insulin concentrations in horses with ID receiving phenylbutazone are mediated by a higher tissue insulin sensitivity.
ANIMALS: Fifteen light breed horses, including seven with ID.
METHODS: Randomized cross-over study. Horses underwent a modified frequently sampled intravenous glucose tolerance test (mFSIGTT) after 8 days of treatment with phenylbutazone (4.4 mg/kg IV daily) or placebo (5 mL 0.9% saline IV daily). After a 10-day washout period, horses received the alternative treatment for 8 days and a second mFSIGTT. Minimal model analysis was performed, and the effects of ID status and phenylbutazone were investigated with p < 0.05 considered significant.
RESULTS: In horses with ID, phenylbutazone increased tissue insulin sensitivity index (median [interquartile range]: 0.39 [0.14-0.74] vs. 0.56 [0.55-1.18] ×10-4 L/mIU/min, p = 0.03), and decreased glucose (21 726 [19 040-24 948] vs. 22 909 [22 496-26 166] mg/dL × min, p = 0.02) and insulin (19 595 [16 147-29 698] vs. 22 752 [20 578-31 826] μIU/mL × min, p = 0.03) areas under the curves. No effect was detected in horses administered placebo.
CONCLUSION AND CLINICAL IMPORTANCE: Phenylbutazone reduces insulin concentration in horses with ID by modulating tissue insulin sensitivity, suggesting that its relevance in the management of ID can extend beyond laminitis-associated pain.
HYPOTHESIS/OBJECTIVES: Investigate the effect of phenylbutazone on tissue insulin sensitivity in horses. It is hypothesized that the reduced glucose and insulin concentrations in horses with ID receiving phenylbutazone are mediated by a higher tissue insulin sensitivity.
ANIMALS: Fifteen light breed horses, including seven with ID.
METHODS: Randomized cross-over study. Horses underwent a modified frequently sampled intravenous glucose tolerance test (mFSIGTT) after 8 days of treatment with phenylbutazone (4.4 mg/kg IV daily) or placebo (5 mL 0.9% saline IV daily). After a 10-day washout period, horses received the alternative treatment for 8 days and a second mFSIGTT. Minimal model analysis was performed, and the effects of ID status and phenylbutazone were investigated with p < 0.05 considered significant.
RESULTS: In horses with ID, phenylbutazone increased tissue insulin sensitivity index (median [interquartile range]: 0.39 [0.14-0.74] vs. 0.56 [0.55-1.18] ×10-4 L/mIU/min, p = 0.03), and decreased glucose (21 726 [19 040-24 948] vs. 22 909 [22 496-26 166] mg/dL × min, p = 0.02) and insulin (19 595 [16 147-29 698] vs. 22 752 [20 578-31 826] μIU/mL × min, p = 0.03) areas under the curves. No effect was detected in horses administered placebo.
CONCLUSION AND CLINICAL IMPORTANCE: Phenylbutazone reduces insulin concentration in horses with ID by modulating tissue insulin sensitivity, suggesting that its relevance in the management of ID can extend beyond laminitis-associated pain.